Nattokinase Powder is quickly becoming a staple in enzyme-based formulations, thanks to its potent fibrinolytic activity and natural origin from fermented soybeans. As brands seek cleaner, plant-derived alternatives with well-documented health relevance, this enzyme stands out for its high bioactivity and standardized units like FU and IU. Increasingly recognized for its role in cardiovascular support and circulation-related products, Nattokinase continues to gain traction across the nutraceutical industry.
Recent studies confirm its potential in maintaining healthy blood flow and breaking down fibrin-based clots naturally without triggering harsh side effects or requiring synthetic additives.
If you're a formulator exploring the enzymatic market, it's worth asking-how does this natural compound compare to other enzymes like Serrapeptase? And which type best suits your formulation goals?
What Is Nattokinase Powder?
Pure Nattokinase Powder stands as a unique enzyme derived from the traditional Japanese food, natto. This enzyme is produced during the fermentation of boiled soybeans by the bacterium Bacillus subtilis var. natto. Unlike other soy-based foods, natto's specific fermentation process yields this potent enzyme, which has garnered attention for its potential health benefits, particularly in cardiovascular health.
The discovery of nattokinase dates back to 1987 when Dr. Hiroyuki Sumi identified its fibrinolytic activity, meaning it can break down fibrin, a protein involved in blood clot formation. This property suggests potential applications in supporting circulatory health.
In industrial settings, Nattokinase Powder is produced through controlled fermentation processes, ensuring consistent enzyme activity and purity. The production involves optimizing various parameters, such as temperature and pH, to maximize yield. For instance, studies have shown that maintaining an inlet air temperature of around 140°C during spray drying can preserve enzyme activity effectively.
Furthermore, advancements in biotechnology have explored cost-effective substrates for nattokinase production. Research indicates that tofu processing wastewater can serve as a viable medium, offering a sustainable approach to enzyme production.
Nattokinase Powder is a specialized enzyme with origins in traditional Japanese cuisine, now produced through refined industrial methods. Its unique properties and potential health benefits make it a subject of ongoing research and interest in the nutraceutical industry.
How Is Nattokinase Powder Produced and Standardized?
Nattokinase powder is produced through a meticulous fermentation process involving Bacillus subtilis subsp. natto, a bacterium known for its ability to produce this potent enzyme. The production process begins with the selection of high-quality soybeans, which are soaked and steamed to prepare them for fermentation. These soybeans are then inoculated with Bacillus subtilis spores and incubated under controlled conditions, typically at 30°C and pH 7.0, for about 26 hours. This environment optimizes the production of nattokinase, achieving activity levels up to 3,284 ± 58 IU/mL .
Following fermentation, the mixture undergoes a series of purification steps. The fermented product is first subjected to centrifugation to separate the solid and liquid components. The liquid, rich in nattokinase, is then filtered and concentrated. To obtain the enzyme in powder form, the concentrate is typically freeze-dried, a method that preserves the enzyme's activity and stability .
Standardization of nattokinase powder is crucial to ensure consistent potency and efficacy. The activity of nattokinase is measured in Fibrinolytic Units (FU), which quantify the enzyme's ability to break down fibrin, a protein involved in blood clotting. One FU is defined as the amount of enzyme that can dissolve a specific quantity of fibrin under standardized conditions . Products are often standardized to contain specific FU levels per gram, such as 2,000 FU/g or 4,000 FU/g, to meet various application requirements.
Quality control is an integral part of the production process. Each batch of nattokinase powder undergoes rigorous testing to verify its enzyme activity, purity, and absence of contaminants. These tests ensure that the final product meets established safety and efficacy standards, making it suitable for use in dietary supplements and functional foods .
Nattokinase vs. Serrapeptase: Which Is Right for You?
In the evolving landscape of enzyme-based supplements, two names often surface in discussions of cardiovascular and anti-inflammatory health: nattokinase and serrapeptase. While both are proteolytic enzymes with impressive bioactivities, they come from vastly different origins, serve distinct physiological functions, and are favored in diverse clinical and nutraceutical applications. Understanding their unique characteristics is essential-not just for health-conscious consumers, but for formulators aiming to design evidence-backed, functionally effective products.
Nattokinase, as its name suggests, is extracted from natto-a traditional Japanese food made by fermenting soybeans with the bacterium Bacillus subtilis natto. During fermentation, this microbe synthesizes nattokinase, an enzyme renowned for its fibrinolytic activity. Essentially, it helps break down fibrin, the fibrous protein responsible for abnormal clot formation in the bloodstream. Due to this ability, nattokinase has attracted considerable interest in cardiovascular wellness circles, particularly in Asia, where traditional foods are often merged with functional medicine. By reducing blood viscosity and supporting smooth blood flow, nattokinase is increasingly being incorporated into heart health supplements and circulatory system support formulations.
In contrast, serrapeptase's story begins not on a dinner table but in the silkworm's gut. Originally discovered in the intestines of silkworms, serrapeptase is produced by Serratia marcescens, a bacterium that helps the worm dissolve its silk cocoon during metamorphosis. Though its natural origin might seem unconventional, its medical relevance is well-documented. Serrapeptase is primarily valued for its potent anti-inflammatory and mucolytic properties. It degrades non-living tissue, blood clots, mucus, and inflammatory proteins, making it a go-to ingredient in supplements targeting joint health, sinus relief, and post-surgical recovery. Over the years, its clinical use has expanded to Europe and North America, where it is typically produced through controlled microbial fermentation to meet GMP standards.
What makes this comparison intriguing is not just their biological source, but how differently they behave in the body. Nattokinase works within the bloodstream, silently breaking down excess fibrin and promoting natural thrombolysis. Its effects are systemic and often long-lasting due to its stable bioavailability, especially when delivered in enteric-coated capsules. Serrapeptase, on the other hand, is often considered more targeted-actively involved in reducing local inflammation, easing pain, and even promoting the resorption of cysts or fibrotic tissues. Clinicians have long debated which enzyme is more effective, but the reality is nuanced: they operate in different biochemical niches and excel in distinct therapeutic contexts.
Of course, no comparison would be complete without addressing safety and compatibility. Both enzymes are generally well-tolerated when used appropriately, though precautions are necessary. Nattokinase, due to its clot-dissolving effects, is not suitable for individuals on anticoagulant therapy or those with bleeding disorders. Likewise, serrapeptase should be used with caution by people taking NSAIDs or blood thinners, given its effect on tissue breakdown and potential to intensify bleeding in rare cases. Importantly, their interaction profiles and safety thresholds should be assessed when designing multi-ingredient formulas. The efficacy of each enzyme can also vary depending on dosage form, delivery system, and the presence of synergistic compounds such as vitamin K2 or magnesium.

For supplement developers or health brands, the question isn't necessarily which enzyme is better-it's which one aligns with the functional goals of the formulation. If the objective is cardiovascular support and healthy blood flow, nattokinase presents a compelling option backed by decades of traditional use and growing clinical data. On the other hand, for applications centered around inflammatory response, immune modulation, or recovery from trauma, serrapeptase offers a versatile and science-backed tool. Some formulations even include both, aiming to leverage the systemic benefits of one alongside the localized actions of the other.
In short, choosing between nattokinase and serrapeptase isn't a matter of superiority-it's a matter of strategy. Each enzyme tells a different biochemical story, responds to a different need, and serves a different purpose in the ever-expanding world of nutraceuticals. Understanding their distinctions is not only vital for effective formulation-it's key to responsible innovation.
FU vs IU: Understanding the Units of Nattokinase
Why the Confusion Exists Around Units
When browsing ingredient labels or reviewing supplier documentation for nattokinase, it's not uncommon to come across two different unit measurements: FU (Fibrinolytic Units) and IU (International Units). To the untrained eye, they may seem interchangeable-or worse, irrelevant-but in reality, they tell us very different things about the enzyme's functional potency. What creates this confusion is a lack of standardization in the global supplement industry. Some brands, particularly in the Asian market, prefer the FU system because it's more directly tied to fibrinolytic activity. Meanwhile, others, especially those targeting international regulatory bodies or wider pharmaceutical applications, lean into IU for consistency with other enzymatic products. But what do these numbers really mean?
The Meaning Behind FU: Activity Over Quantity
FU, short for Fibrinolytic Units, is a measurement specifically developed to quantify nattokinase's ability to break down fibrin-the fibrous protein responsible for blood clot formation. One FU reflects a very specific enzymatic activity level in vitro, as determined under standardized lab conditions. The more FUs per gram, the stronger the enzyme is in fibrinolytic function. This means FU is inherently tied to function, not mass. For instance, two samples of nattokinase powder may have the same weight in milligrams, but drastically different FU ratings depending on how active and well-preserved the enzyme is. Manufacturers and researchers often use FU when testing therapeutic potential or comparing bioefficacy across different fermentation batches. It's not just a number; it's a measure of actual biological power.
Understanding IU: Standardization Across Borders
On the other hand, IU-International Unit-is a broader, globally accepted metric used to quantify the biological effect of various substances, from vitamins to enzymes. In theory, one IU of an enzyme like nattokinase should correspond to a standardized level of biological activity. However, here's where things get messy: not all enzymes have clearly defined IU-to-activity conversion ratios, especially those like nattokinase that aren't yet universally codified by major pharmacopoeias. In practice, this means different manufacturers might use different internal calibration standards, leading to variability in IU labeling unless there's an agreed-upon regulatory benchmark. This makes IU attractive for regulatory submissions and product labels targeting pharmaceutical-style consistency, but it can obscure the actual functional performance when comparing across different products.
The Challenge of Conversion: FU ≠ IU
Can FU be converted into IU? In some cases, manufacturers will offer an approximate conversion, often suggesting that 2,000 FU corresponds to around 100 IU, depending on the assay used. But these figures are not universal. Because FU focuses on specific fibrinolytic activity and IU is based on broader bioactivity measurements (sometimes across different biological systems), converting between the two can be misleading unless you're deeply familiar with the testing method behind each number. This is why it's so important for formulators and buyers to ask detailed technical questions when sourcing nattokinase-what's the assay protocol? What substrate was used? Was it tested in plasma or synthetic fibrin? Only with this context can you confidently interpret the units being offered.
So, Which Unit Should You Choose?
For formulators focused on cardiovascular health and clot-dissolution functionality, FU may offer a more precise lens through which to evaluate nattokinase potency. It directly answers the question: "How effectively does this enzyme break down fibrin?" If the formulation's goal is to offer measurable circulatory support, FU is arguably the more functional choice. But for brands prioritizing regulatory alignment, especially those marketing in multiple countries or seeking pharmaceutical-grade consistency, IU may be a more acceptable standard-albeit one that requires a deeper understanding of the manufacturer's test protocols. In short, neither unit is inherently superior. The right choice depends on your formulation goals, regional market regulations, and how transparent your supplier is with their testing methodology.
Practical Implications for Buyers and Brands
What this all means is that unit literacy is not just technical trivia-it's essential. Choosing the wrong specification, or failing to understand what those numbers mean, can result in underperforming products or misleading marketing claims. Brands that treat these unit differences casually risk losing credibility with informed consumers, especially in a market where health-conscious buyers are increasingly scrutinizing labels. That's why ingredient professionals must move beyond surface-level comparisons and dig into the analytics behind the units. Ask suppliers for COAs that specify the exact test method. Demand side-by-side data. And if you're serious about efficacy, don't just look at IU or FU-look at both, and ask why one was chosen over the other.
Buy Nattokinase Powder
Whether you're formulating a functional food blend, crafting a cardiovascular support supplement, or simply aiming to elevate your nutraceutical portfolio, a well-standardized nattokinase ingredient makes all the difference. At its best, this enzyme doesn't just meet expectations-it redefines what targeted circulatory support can look like. With multiple specification options ranging from 5,000 FU up to 40,000 FU, food-grade quality, and a clean powder appearance from white to pale yellow, the versatility of this ingredient allows it to fit seamlessly into diverse applications. And when it comes to formulation flexibility, it's not just about activity-it's about reliability, scalability, and knowing that what you see on the spec sheet will hold up batch after batch.
Nattokinase Powder from Xi'an Le-Nutra Ingredients is backed by over a decade of industry experience and a commitment to traceable sourcing and precise enzymatic testing. Whether you're scaling up a new line or optimizing an existing formulation, our team provides more than just ingredients-we offer insight, consistency, and dependable service. For technical specifications, pricing, or bulk ordering inquiries, reach out directly to us at 📩 info@lenutra.com. Let's build better formulations together-rooted in science, and powered by quality.
References:
1. Fujita, M., Hong, K., Ito, Y., Misawa, S., Takeuchi, N., Kariya, K., & Nishimuro, S. (1995). Transport of nattokinase across the rat intestinal tract. Biological & Pharmaceutical Bulletin, 18(9), 1194–1196.
2. Sumi, H., Hamada, H., Nakanishi, K., & Hiratani, H. (1990). Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematologica, 84(3), 139–143.
3. Sumi, H., Hamada, H., Tsushima, H., Mihara, H., & Muraki, H. (1987). A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia, 43(10), 1110-1111.
4. Zhang, Y., et al. (2021). Microencapsulation of nattokinase from fermentation by spray drying: Optimization, comprehensive score, and stability. Frontiers in Nutrition, 8, 826961.
5. Li, Y., et al. (2021). Tofu processing wastewater as a low-cost substrate for high activity nattokinase production using Bacillus subtilis. BMC Biotechnology, 21(1), 1-12.
6. Yoo, J. S., et al. (2019). Isolation and Optimal Fermentation Condition of the Bacillus subtilis WTC016 for Nattokinase Production. Fermentation, 5(4), 92.(mdpi.com)
7. Google Patents. (2010). Process for producing Bacillus subtilis natto and/or nattokinase and the product thereof. TW201000629A.(patents.google.com)
8. Drugs.com. (n.d.). Nattokinase Uses, Benefits & Dosage.(drugs.com)
9. Jagathy, K., Sherly, J. N., & Rajeshkumar, S. (2017). Production of Nattokinase from Bacillus subtilis - optimization and purification by liquid-liquid extraction. Research Journal of Pharmacy and Technology, 10(6), 1934-1938.(rjptonline.org)
10. Sumi, H., Hamada, H., Tsushima, H., Mihara, H., & Muraki, H. (1987). A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia, 43(10), 1110–1111.
11. Kee, W. H., Tan, S. L., Lee, V., & Salmon, Y. M. (1989). The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Medical Journal, 30(1), 48–54.
12. Bhagat, R. M., Sharma, A., & Rao, A. V. (2020). Enzymatic anti-inflammatory therapies: Nattokinase and Serrapeptase as a potential future drug. Current Trends in Biomedical Engineering & Biosciences, 20(5), 555598.
13. Sumi, H., et al. (1987). A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia, 43(10), 1110–1111.
14. Fujita, M., et al. (1995). Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the traditional Japanese food Natto. Journal of Fermentation and Bioengineering, 80(2), 155–160.
15. Nagaoka, S., & Miwa, Y. (2020). Analytical challenges and emerging methods for the standardization of nattokinase in dietary supplements. Current Pharmaceutical Analysis, 16(3), 300–307.
